Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis

DOI record: { "DOI": "10.1007/s10875-020-00911-6", "ISSN": [ "0271-9142", "1573-2592" ], "URL": "http://dx.doi.org/10.1007/s10875-020-00911-6", "alternative-id": [ "911" ], "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "15 July 2020" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "3 November 2020" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "14 November 2020" }, { "group": { "label": "Compliance with Ethical Standards", "name": "EthicsHeading" }, "name": "Ethics", "order": 1 }, { "group": { "label": "Conflict of Interest", "name": "EthicsHeading" }, "name": "Ethics", "order": 2, "value": "MR: investigator of NCT04315298 trial which investigates the efficacy and safety of sarilumab (licensed by Sanofi) in hospitalized patients with COVID-19; non-financial support from Novartis Pharma SAS, Bristol Myers Squibb, and Swedish Orphan Biovitrum (outside the submitted work). HS: non-financial support from Oxyvie; grants for Foch Foundation, Fonds de dotation pour la recherche en santé respiratoire, and Philips Foundation (outside the submitted work). GG: non-financial support from Bard (outside the submitted work). YS: non-financial support from Astra Zeneca, Novartis Pharma, Bristol Myers Squibb, Sanofi Aventis France, Shire France, Chugai Pharma France, and Pfizer SAS (outside the submitted work). JLC: personal fees and non-financial support from Novartis, Boehringer Ingelheim, and Astra Zeneca; grants and other from LVL Air Liquide, outside the submitted work. JEK: none. MG: consulting fees from GlaxoSmithKline and Astra Zeneca (outside the submitted work). FA: investigator of NCT04315298 trial which investigates the efficacy and safety of sarilumab (licensed by Sanofi) in hospitalized patients with COVID-19. All other authors declare that they have no conflict of interest." }, { "label": "Free to read", "name": "free", "value": "This content has been made available to all." } ], "author": [ { "affiliation": [], "name": "on behalf of the Foch COVID-19 Study Group", "sequence": "first" }, { "affiliation": [], "family": "Roumier", "given": "Mathilde", "sequence": "first" }, { "affiliation": [], "family": "Paule", "given": "Romain", "sequence": "additional" }, { "affiliation": [], "family": "Vallée", "given": "Alexandre", "sequence": "additional" }, { "affiliation": [], "family": "Rohmer", "given": "Julien", "sequence": "additional" }, { "affiliation": [], "family": "Ballester", "given": "Marie", "sequence": "additional" }, { "affiliation": [], "family": "Brun", "given": "Anne-Laure", "sequence": "additional" }, { "affiliation": [], "family": "Cerf", "given": "Charles", "sequence": "additional" }, { "affiliation": [], "family": "Chabi", "given": "Marie-Laure", "sequence": "additional" }, { "affiliation": [], "family": "Chinet", "given": "Thierry", "sequence": "additional" }, { "affiliation": [], "family": "Colombier", "given": "Marie-Alice", "sequence": "additional" }, { "affiliation": [], "family": "Farfour", "given": "Eric", "sequence": "additional" }, { "affiliation": [], "family": "Fourn", "given": "Erwan", "sequence": "additional" }, { "affiliation": [], "family": "Géri", "given": "Guillaume", "sequence": "additional" }, { "affiliation": [], "family": "Khau", "given": "David", "sequence": "additional" }, { "affiliation": [], "family": "Marroun", "given": "Ibrahim", "sequence": "additional" }, { "affiliation": [], "family": "Ponsoye", "given": "Matthieu", "sequence": "additional" }, { "affiliation": [], "family": "Roux", "given": "Antoine", "sequence": "additional" }, { "affiliation": [], "family": "Salvator", "given": "Hélène", "sequence": "additional" }, { "affiliation": [], "family": "Schoindre", "given": "Yoland", "sequence": "additional" }, { "affiliation": [], "family": "Si Larbi", "given": "Anne-Gaëlle", "sequence": "additional" }, { "affiliation": [], "family": "Tchérakian", "given": "Colas", "sequence": "additional" }, { "affiliation": [], "family": "Vasse", "given": "Marc", "sequence": "additional" }, { "affiliation": [], "family": "Verrat", "given": "Anne", "sequence": "additional" }, { "affiliation": [], "family": "Zuber", "given": "Benjamin", "sequence": "additional" }, { "affiliation": [], "family": "Couderc", "given": "Louis-Jean", "sequence": "additional" }, { "affiliation": [], "family": "Kahn", "given": "Jean-Emmanuel", "sequence": "additional" }, { "affiliation": [], "family": "Groh", "given": "Matthieu", "sequence": "additional" }, { "affiliation": [], "family": "Ackermann", "given": "Félix", "sequence": "additional" } ], "container-title": "Journal of Clinical Immunology", "container-title-short": "J Clin Immunol", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2020, 11, 14 ] ], "date-time": "2020-11-14T01:02:28Z", "timestamp": 1605315748000 }, "deposited": { "date-parts": [ [ 2021, 2, 3 ] ], "date-time": "2021-02-03T16:11:19Z", "timestamp": 1612368679000 }, "indexed": { "date-parts": [ [ 2025, 5, 27 ] ], "date-time": "2025-05-27T18:26:17Z", "timestamp": 1748370377793 }, "is-referenced-by-count": 36, "issue": "2", "issued": { "date-parts": [ [ 2020, 11, 14 ] ] }, "journal-issue": { "issue": "2", "published-print": { "date-parts": [ [ 2021, 2 ] ] } }, "language": "en", "license": [ { "URL": "http://www.springer.com/tdm", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 11, 14 ] ], "date-time": "2020-11-14T00:00:00Z", "timestamp": 1605312000000 } }, { "URL": "http://www.springer.com/tdm", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 11, 14 ] ], "date-time": "2020-11-14T00:00:00Z", "timestamp": 1605312000000 } } ], "link": [ { "URL": "http://link.springer.com/content/pdf/10.1007/s10875-020-00911-6.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "http://link.springer.com/article/10.1007/s10875-020-00911-6/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "http://link.springer.com/content/pdf/10.1007/s10875-020-00911-6.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "page": "303-314", "prefix": "10.1007", "published": { "date-parts": [ [ 2020, 11, 14 ] ] }, "published-online": { "date-parts": [ [ 2020, 11, 14 ] ] }, "published-print": { "date-parts": [ [ 2021, 2 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.1093/cid/ciaa248", "author": "C Qin", "doi-asserted-by": "publisher", "first-page": "762", "issue": "15", "journal-title": "Clin Infect Dis", "key": "911_CR1", "unstructured": "Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762–8.", "volume": "71", "year": "2020" }, { "DOI": "10.1182/blood.2020006000", "author": "JM Connors", "doi-asserted-by": "publisher", "first-page": "2033", "issue": "23", "journal-title": "Blood", "key": "911_CR2", "unstructured": "Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–40.", "volume": "135", "year": "2020" }, { "DOI": "10.1016/S0140-6736(20)30628-0", "author": "P Mehta", "doi-asserted-by": "publisher", "first-page": "1033", "issue": "10229", "journal-title": "Lancet", "key": "911_CR3", "unstructured": "Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4.", "volume": "395", "year": "2020" }, { "DOI": "10.1016/S0140-6736(20)30566-3", "author": "F Zhou", "doi-asserted-by": "publisher", "first-page": "1054", "issue": "10229", "journal-title": "Lancet", "key": "911_CR4", "unstructured": "Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.", "volume": "395", "year": "2020" }, { "DOI": "10.1128/IAI.72.8.4410-4415.2004", "author": "Y Zhang", "doi-asserted-by": "publisher", "first-page": "4410", "issue": "8", "journal-title": "Infect Immun", "key": "911_CR5", "unstructured": "Zhang Y, Li J, Zhan Y, Wu L, Yu X, Zhang W, et al. Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect Immun. 2004;72(8):4410–5.", "volume": "72", "year": "2004" }, { "DOI": "10.1002/jmv.25770", "author": "Y Gao", "doi-asserted-by": "publisher", "first-page": "791", "issue": "7", "journal-title": "J Med Virol", "key": "911_CR6", "unstructured": "Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020;92(7):791–6.", "volume": "92", "year": "2020" }, { "DOI": "10.1073/pnas.2005615117", "author": "X Xu", "doi-asserted-by": "publisher", "first-page": "10970", "issue": "20", "journal-title": "Proc Natl Acad Sci U S A", "key": "911_CR7", "unstructured": "Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970–5.", "volume": "117", "year": "2020" }, { "DOI": "10.1016/j.chom.2020.04.009", "author": "EJ Giamarellos-Bourboulis", "doi-asserted-by": "publisher", "first-page": "992", "issue": "6", "journal-title": "Cell Host Microbe", "key": "911_CR8", "unstructured": "Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27(6):992–1000.e3.", "volume": "27", "year": "2020" }, { "DOI": "10.1080/14712598.2017.1346078", "author": "JD Cañete", "doi-asserted-by": "publisher", "first-page": "1089", "issue": "9", "journal-title": "Expert Opin Biol Ther", "key": "911_CR9", "unstructured": "Cañete JD, Hernández MV, Sanmartí R. Safety profile of biological therapies for treating rheumatoid arthritis. Expert Opin Biol Ther. 2017;17(9):1089–103.", "volume": "17", "year": "2017" }, { "key": "911_CR10", "unstructured": "Susen S, Tacquard CA, Godon A, Mansour A, Nguyen P, Godier A, et al. Traitement anticoagulant pour la prévention du risque thrombotique chez un patient hospitalisé avec COVID-19 et surveillance de l’hémostase propositions du GIHP et du GFHT. https://www.portailvasculaire.fr/sites/default/files/docs/covid-19_gihp-gfht-3_avril_final.pdf." }, { "key": "911_CR11", "unstructured": "SRLF-SFAR-SFMU-GFRUP-SPILF-SPLF. Recommandations d’experts portant sur la prise en charge en réanimation des patients en période d’épidémie à SARS-CoV2. Avr. 2020. https://www.srlf.org/wp-content/uploads/2020/04/RFE-COVID_V4.pdf." }, { "DOI": "10.1001/jama.2015.13480", "author": "JS Haukoos", "doi-asserted-by": "publisher", "first-page": "1637", "issue": "15", "journal-title": "JAMA.", "key": "911_CR12", "unstructured": "Haukoos JS, Lewis RJ. The propensity score. JAMA. 2015;314(15):1637–8.", "volume": "314", "year": "2015" }, { "DOI": "10.1001/jamainternmed.2020.0994", "author": "C Wu", "doi-asserted-by": "publisher", "first-page": "934", "issue": "7", "journal-title": "JAMA Intern Med", "key": "911_CR13", "unstructured": "Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–43.", "volume": "180", "year": "2020" }, { "key": "911_CR14", "unstructured": "Zhao X, Zhang B, Li P, Ma C, Gu J, Hou P, et al. Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and meta-analysis. medRxiv. 2020;2020.03.17.20037572." }, { "DOI": "10.1056/NEJMoa2001282", "author": "B Cao", "doi-asserted-by": "publisher", "first-page": "1787", "issue": "19", "journal-title": "N Engl J Med", "key": "911_CR15", "unstructured": "Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–99.", "volume": "382", "year": "2020" }, { "DOI": "10.1136/bmj.m1844", "author": "M Mahévas", "doi-asserted-by": "publisher", "first-page": "m1844", "journal-title": "BMJ.", "key": "911_CR16", "unstructured": "Mahévas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2020;369:m1844.", "volume": "369", "year": "2020" }, { "DOI": "10.1016/S0140-6736(20)31042-4", "author": "IF-N Hung", "doi-asserted-by": "publisher", "first-page": "1695", "issue": "10238", "journal-title": "Lancet.", "key": "911_CR17", "unstructured": "Hung IF-N, Lung K-C, Tso EY-K, Liu R, Chung TW-H, Chu M-Y, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695–704.", "volume": "395", "year": "2020" }, { "key": "911_CR18", "unstructured": "Pan H, Peto R, Abdool Karim Q, Alejandria M, Henao Restrepo AM, Hernandez Garcia C, et al. Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results. medRxiv. 2020;2020.10.15.20209817." }, { "DOI": "10.1016/S0140-6736(20)31022-9", "author": "Y Wang", "doi-asserted-by": "publisher", "first-page": "1569", "issue": "10236", "journal-title": "Lancet.", "key": "911_CR19", "unstructured": "Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–78.", "volume": "395", "year": "2020" }, { "DOI": "10.1056/NEJMoa2007764", "author": "JH Beigel", "doi-asserted-by": "publisher", "first-page": "1813", "journal-title": "N Engl J Med", "key": "911_CR20", "unstructured": "Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;NEJMoa2007764:1813–26. https://doi.org/10.1056/NEJMoa2007764.", "volume": "NEJMoa2007764", "year": "2020" }, { "DOI": "10.1016/S2213-2600(20)30079-5", "author": "X Yang", "doi-asserted-by": "publisher", "first-page": "475", "issue": "5", "journal-title": "Lancet Respir Med", "key": "911_CR21", "unstructured": "Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–81.", "volume": "8", "year": "2020" }, { "DOI": "10.1016/j.autrev.2020.102568", "author": "P Toniati", "doi-asserted-by": "publisher", "first-page": "102568", "issue": "7", "journal-title": "Autoimmun Rev", "key": "911_CR22", "unstructured": "Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19(7):102568.", "volume": "19", "year": "2020" }, { "DOI": "10.1016/j.ejim.2020.05.009", "author": "R Capra", "doi-asserted-by": "publisher", "first-page": "31", "journal-title": "Eur J Intern Med", "key": "911_CR23", "unstructured": "Capra R, De Rossi N, Mattioli F, Romanelli G, Scarpazza C, Sormani MP, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med. 2020;76:31–5.", "volume": "76", "year": "2020" }, { "DOI": "10.1016/j.ejim.2020.05.021", "author": "C Campochiaro", "doi-asserted-by": "publisher", "first-page": "43", "journal-title": "Eur J Intern Med", "key": "911_CR24", "unstructured": "Campochiaro C, Della-Torre E, Cavalli G, De Luca G, Ripa M, Boffini N, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020;76:43–9.", "volume": "76", "year": "2020" }, { "DOI": "10.1016/S2665-9913(20)30173-9", "author": "G Guaraldi", "doi-asserted-by": "publisher", "first-page": "e474", "issue": "8", "journal-title": "Lancet Rheumatol", "key": "911_CR25", "unstructured": "Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2(8):e474–84.", "volume": "2", "year": "2020" }, { "DOI": "10.1093/cid/ciaa954", "doi-asserted-by": "publisher", "key": "911_CR26", "unstructured": "Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis. 2020;ciaa954. https://doi.org/10.1093/cid/ciaa954." }, { "DOI": "10.1016/S2665-9913(20)30277-0", "author": "N Biran", "doi-asserted-by": "publisher", "first-page": "e603", "issue": "10", "journal-title": "Lancet Rheumatol", "key": "911_CR27", "unstructured": "Biran N, Ip A, Ahn J, Go RC, Wang S, Mathura S, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol. 2020;2(10):e603–12.", "volume": "2", "year": "2020" }, { "DOI": "10.1016/j.reuma.2020.06.003", "author": "L Figuero-Pérez", "doi-asserted-by": "publisher", "first-page": "30142", "issue": "20", "journal-title": "Reumatol Clin", "key": "911_CR28", "unstructured": "Figuero-Pérez L, Olivares-Hernández A, Escala-Cornejo RA, Terán-Brage E, López-Gutiérrez Á, Cruz-Hernández JJ. Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab. Reumatol Clin. 2020;S1699-258X(20):30142–X. https://doi.org/10.1016/j.reuma.2020.06.003.", "volume": "S1699-258X", "year": "2020" }, { "DOI": "10.1111/bjh.16979", "doi-asserted-by": "publisher", "key": "911_CR29", "unstructured": "Innes AJ, Cook LB, Marks S, Bataillard E, Crossette-Thambiah C, Sivasubramaniam G, et al. Ruxolitinib for tocilizumab-refractory severe COVID-19 infection. Br J Haematol. 2020;190. https://doi.org/10.1111/bjh.16979." }, { "DOI": "10.1016/j.chest.2020.04.024", "author": "J Radbel", "doi-asserted-by": "publisher", "first-page": "e15", "issue": "1", "journal-title": "Chest.", "key": "911_CR30", "unstructured": "Radbel J, Narayanan N, Bhatt PJ. Use of tocilizumab for COVID-19-induced cytokine release syndrome: a cautionary case report. Chest. 2020;158(1):e15–9.", "volume": "158", "year": "2020" }, { "DOI": "10.3390/microorganisms8050695", "doi-asserted-by": "crossref", "key": "911_CR31", "unstructured": "Colaneri M, Bogliolo L, Valsecchi P, Sacchi P, Zuccaro V, Brandolino F, et al. Tocilizumab for treatment of severe COVID-19 patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms. 2020;8(5):695." }, { "key": "911_CR32", "unstructured": "Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra® in hospitalised patients with severe COVID-19 associated pneumonia. 2020. Available at: https://www.roche.com/investors/updates/inv-update-2020-07-29.htm. Accessed October 10th 2020." }, { "DOI": "10.5005/jsd-10-1-iv", "doi-asserted-by": "crossref", "key": "911_CR33", "unstructured": "Sanofi provides update on Kevzara® (sarilumab) phase 3 trial in severe and critically ill COVID-19 patients outside the U.S. 2020. Available at: https://www.sanofigenzyme.com/about-us/newsroom/2020/2020-09-01-00-00-00. Accessed October 10th 2020." }, { "DOI": "10.1016/j.jaci.2020.09.018", "author": "JM Galván-Román", "doi-asserted-by": "publisher", "first-page": "31329", "issue": "20", "journal-title": "J Allergy Clin Immunol", "key": "911_CR34", "unstructured": "Galván-Román JM, Rodríguez-García SC, Roy-Vallejo E, Marcos-Jiménez A, Sánchez-Alonso S, Fernández-Díaz C, et al. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: an observational study. J Allergy Clin Immunol. 2020;S0091–6749(20):31329–4. https://doi.org/10.1016/j.jaci.2020.09.018.", "volume": "S0091–6749", "year": "2020" }, { "DOI": "10.1136/annrheumdis-2020-217706", "author": "A Aouba", "doi-asserted-by": "publisher", "first-page": "1381", "issue": "10", "journal-title": "Ann Rheum Dis", "key": "911_CR35", "unstructured": "Aouba A, Baldolli A, Geffray L, Verdon R, Bergot E, Martin-Silva N, et al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. Ann Rheum Dis. 2020;79(10):1381–2.", "volume": "79", "year": "2020" }, { "DOI": "10.1016/S2665-9913(20)30164-8", "author": "T Huet", "doi-asserted-by": "publisher", "first-page": "e393", "issue": "7", "journal-title": "Lancet Rheumatol", "key": "911_CR36", "unstructured": "Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020;2(7):e393–400.", "volume": "2", "year": "2020" }, { "DOI": "10.1016/S2665-9913(20)30127-2", "author": "G Cavalli", "doi-asserted-by": "publisher", "first-page": "e325", "issue": "6", "journal-title": "Lancet Rheumatol", "key": "911_CR37", "unstructured": "Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325–31.", "volume": "2", "year": "2020" }, { "DOI": "10.1016/j.jaci.2020.05.019", "author": "Y Cao", "doi-asserted-by": "publisher", "first-page": "137", "issue": "1", "journal-title": "J Allergy Clin Immunol", "key": "911_CR38", "unstructured": "Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol. 2020;146(1):137–146.e3.", "volume": "146", "year": "2020" }, { "DOI": "10.1016/S2665-9913(20)30170-3", "author": "G De Luca", "doi-asserted-by": "publisher", "first-page": "e465", "issue": "8", "journal-title": "Lancet Rheumatol", "key": "911_CR39", "unstructured": "De Luca G, Cavalli G, Campochiaro C, Della-Torre E, Angelillo P, Tomelleri A, et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol. 2020;2(8):e465–73.", "volume": "2", "year": "2020" }, { "DOI": "10.1001/jama.2020.17022", "author": "DC Angus", "doi-asserted-by": "publisher", "first-page": "1317", "issue": "13", "journal-title": "JAMA.", "key": "911_CR40", "unstructured": "Writing Committee for the REMAP-CAP Investigators, Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324(13):1317–29. https://doi.org/10.1001/jama.2020.17022.", "volume": "324", "year": "2020" }, { "DOI": "10.1001/jama.2020.16761", "author": "P-F Dequin", "doi-asserted-by": "publisher", "first-page": "1", "issue": "13", "journal-title": "JAMA.", "key": "911_CR41", "unstructured": "Dequin P-F, Heming N, Meziani F, Plantefève G, Voiriot G, Badié J, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2020;324(13):1–9. https://doi.org/10.1001/jama.2020.16761.", "volume": "324", "year": "2020" }, { "DOI": "10.1001/jama.2020.17021", "author": "BM Tomazini", "doi-asserted-by": "publisher", "first-page": "1", "issue": "13", "journal-title": "JAMA.", "key": "911_CR42", "unstructured": "Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324(13):1–11. https://doi.org/10.1001/jama.2020.17021.", "volume": "324", "year": "2020" }, { "DOI": "10.1056/NEJMoa2021436", "doi-asserted-by": "publisher", "key": "911_CR43", "unstructured": "RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. 2020;NEJMoa2021436. https://doi.org/10.1056/NEJMoa2021436." }, { "DOI": "10.1001/jama.2020.17023", "author": "JAC Sterne", "doi-asserted-by": "publisher", "first-page": "1", "issue": "13", "journal-title": "JAMA", "key": "911_CR44", "unstructured": "WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1–13. https://doi.org/10.1001/jama.2020.17023.", "volume": "324", "year": "2020" } ], "reference-count": 44, "references-count": 44, "relation": {}, "resource": { "primary": { "URL": "http://link.springer.com/10.1007/s10875-020-00911-6" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "volume": "41" }